vs
Side-by-side financial comparison of Claritev Corp (CTEV) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $164.7M, roughly 1.5× PTC THERAPEUTICS, INC.). Claritev Corp runs the higher net margin — -32.7% vs -82.0%, a 49.3% gap on every dollar of revenue. On growth, Claritev Corp posted the faster year-over-year revenue change (6.2% vs -22.7%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $-36.6M). Over the past eight quarters, Claritev Corp's revenue compounded faster (2.5% CAGR vs -11.5%).
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
CTEV vs PTCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $164.7M |
| Net Profit | $-80.6M | $-135.0M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | -43.3% |
| Net Margin | -32.7% | -82.0% |
| Revenue YoY | 6.2% | -22.7% |
| Net Profit YoY | 41.6% | -104.8% |
| EPS (diluted) | $-4.88 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.6M | $164.7M | ||
| Q3 25 | $246.0M | $211.0M | ||
| Q2 25 | $241.6M | $178.9M | ||
| Q1 25 | $231.3M | $1.2B | ||
| Q4 24 | $232.1M | $213.2M | ||
| Q3 24 | $230.5M | $196.8M | ||
| Q2 24 | $233.5M | $186.7M | ||
| Q1 24 | $234.5M | $210.1M |
| Q4 25 | $-80.6M | $-135.0M | ||
| Q3 25 | $-69.8M | $15.9M | ||
| Q2 25 | $-62.6M | $-64.8M | ||
| Q1 25 | $-71.3M | $866.6M | ||
| Q4 24 | $-138.0M | $-65.9M | ||
| Q3 24 | $-391.4M | $-106.7M | ||
| Q2 24 | $-576.7M | $-99.2M | ||
| Q1 24 | $-539.7M | $-91.6M |
| Q4 25 | -3.1% | -43.3% | ||
| Q3 25 | 4.1% | 1.4% | ||
| Q2 25 | 6.9% | -19.5% | ||
| Q1 25 | 4.2% | 82.5% | ||
| Q4 24 | -17.8% | -76.2% | ||
| Q3 24 | -146.7% | -27.7% | ||
| Q2 24 | -224.4% | -21.5% | ||
| Q1 24 | -207.4% | -21.6% |
| Q4 25 | -32.7% | -82.0% | ||
| Q3 25 | -28.4% | 7.5% | ||
| Q2 25 | -25.9% | -36.3% | ||
| Q1 25 | -30.8% | 73.7% | ||
| Q4 24 | -59.4% | -30.9% | ||
| Q3 24 | -169.8% | -54.2% | ||
| Q2 24 | -247.0% | -53.1% | ||
| Q1 24 | -230.1% | -43.6% |
| Q4 25 | $-4.88 | $-1.63 | ||
| Q3 25 | $-4.23 | $0.20 | ||
| Q2 25 | $-3.81 | $-0.83 | ||
| Q1 25 | $-4.38 | $10.04 | ||
| Q4 24 | $-8.49 | $-0.85 | ||
| Q3 24 | $-24.25 | $-1.39 | ||
| Q2 24 | $-35.78 | $-1.29 | ||
| Q1 24 | $-33.40 | $-1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $1.9B |
| Total DebtLower is stronger | $4.6B | — |
| Stockholders' EquityBook value | $-173.9M | $-205.3M |
| Total Assets | $4.9B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.8M | $1.9B | ||
| Q3 25 | $39.2M | $1.7B | ||
| Q2 25 | $56.4M | $2.0B | ||
| Q1 25 | $23.1M | $2.0B | ||
| Q4 24 | $16.8M | $1.1B | ||
| Q3 24 | $86.6M | $1.0B | ||
| Q2 24 | $48.8M | $1.1B | ||
| Q1 24 | $58.7M | $884.8M |
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $-173.9M | $-205.3M | ||
| Q3 25 | $-101.8M | $-155.8M | ||
| Q2 25 | $-39.9M | $-206.5M | ||
| Q1 25 | $14.8M | $-185.8M | ||
| Q4 24 | $84.0M | $-1.1B | ||
| Q3 24 | $207.6M | $-1.1B | ||
| Q2 24 | $603.4M | $-980.2M | ||
| Q1 24 | $1.2B | $-893.9M |
| Q4 25 | $4.9B | $2.9B | ||
| Q3 25 | $5.0B | $2.6B | ||
| Q2 25 | $5.1B | $2.6B | ||
| Q1 25 | $5.1B | $2.7B | ||
| Q4 24 | $5.2B | $1.7B | ||
| Q3 24 | $5.3B | $1.8B | ||
| Q2 24 | $5.7B | $1.9B | ||
| Q1 24 | $6.4B | $1.8B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — | ||
| Q1 24 | 3.85× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | $-34.3M |
| Free Cash FlowOCF − Capex | $36.4M | $-36.6M |
| FCF MarginFCF / Revenue | 14.8% | -22.3% |
| Capex IntensityCapex / Revenue | 12.1% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | $-34.3M | ||
| Q3 25 | $19.9M | $-66.3M | ||
| Q2 25 | $61.2M | $-58.3M | ||
| Q1 25 | $-30.1M | $870.1M | ||
| Q4 24 | $-33.4M | $-30.0M | ||
| Q3 24 | $72.8M | $-77.0M | ||
| Q2 24 | $18.5M | $-71.5M | ||
| Q1 24 | $49.7M | $70.8M |
| Q4 25 | $36.4M | $-36.6M | ||
| Q3 25 | $-16.3M | $-69.7M | ||
| Q2 25 | $36.6M | $-59.6M | ||
| Q1 25 | $-68.9M | $868.4M | ||
| Q4 24 | $-63.8M | $-33.8M | ||
| Q3 24 | $41.1M | $-77.5M | ||
| Q2 24 | $-7.0M | $-78.8M | ||
| Q1 24 | $19.2M | $61.2M |
| Q4 25 | 14.8% | -22.3% | ||
| Q3 25 | -6.6% | -33.1% | ||
| Q2 25 | 15.2% | -33.3% | ||
| Q1 25 | -29.8% | 73.8% | ||
| Q4 24 | -27.5% | -15.8% | ||
| Q3 24 | 17.8% | -39.4% | ||
| Q2 24 | -3.0% | -42.2% | ||
| Q1 24 | 8.2% | 29.1% |
| Q4 25 | 12.1% | 1.4% | ||
| Q3 25 | 14.7% | 1.6% | ||
| Q2 25 | 10.2% | 0.7% | ||
| Q1 25 | 16.8% | 0.1% | ||
| Q4 24 | 13.1% | 1.8% | ||
| Q3 24 | 13.8% | 0.3% | ||
| Q2 24 | 10.9% | 4.0% | ||
| Q1 24 | 13.0% | 4.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | -4.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
